U.S. markets closed

Helix BioPharma Corp. (HBPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.77330.0000 (0.00%)
At close: 10:03AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7733
Open0.7733
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7733 - 0.7733
52 Week Range0.2200 - 0.8800
Volume813
Avg. Volume192
Market Cap73.059M
Beta (5Y Monthly)-0.16
PE Ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million
    ACCESSWIRE

    Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million

    RICHMOND HILL, ON / ACCESSWIRE / May 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, "Lind") for gross proceeds of CAD$3.

  • Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million
    ACCESSWIRE

    Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

    RICHMOND HILL, ON / ACCESSWIRE / May 11, 2021 / Helix BioPharma Corp.(TSX:HBP)("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, "Lind").

  • Helix BioPharma Corp. Extends Period to Exercise Warrants
    ACCESSWIRE

    Helix BioPharma Corp. Extends Period to Exercise Warrants

    RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties.